Susumu M Tonegawa
age ~85
from Chestnut Hill, MA
Susumu Tonegawa Phones & Addresses
- 101 Chestnut Hill Rd, Chestnut Hill, MA 02467 • (617)7396993
- Boston, MA
- Waterville Valley, NH
- Newton, MA
- Sibley, IL
- Boston Clg, MA
Name / Title
Company / Classification
Phones & Addresses
President
MAYSUM, INCORPORATED
11 Hobart Rd, Newton, MA
Wikipedia
Jerry Adams
view source…Their research, following that by Susumu Tonegawa, also led to the discovery that antibody genes encode as bits and pieces, that can recombine in a myriad of ways to help fight infection; they also confirmed earlier work by Shen-Ong & Cole, Leder, Hood, Croce, and Hayward that genetic mutati...
Susumu Tegawa
view sourceSusumu Tonegawa ( Tonegawa Susumu, born September 6, 1939) is a Japanese scientist who won the Nobel Prize for Physiology or Medicine in 1987 for ...
Us Patents
-
Identifying Calcineurin Activators For Treatment Of Schizophrenia
view source -
US Patent:7935500, May 3, 2011
-
Filed:Mar 26, 2003
-
Appl. No.:10/400348
-
Inventors:David J. Gerber - Somerville MA, US
Maria Karayiorgou - Riverdale NY, US
Tsuyoshi Miyakawa - Aichi, JP
Susumu Tonegawa - Chestnut Hill MA, US -
Assignee:Massachusetts Institute of Technology - Cambridge MA
Rockefeller University - New York NY -
International Classification:C12Q 1/34
C12Q 1/68
C12Q 1/02
G01N 33/53
G01N 33/15 -
US Classification:435 18, 435 6, 435 71, 435 29, 800 3
-
Abstract:The present invention provides targets, methods, and reagents for the diagnosis and treatment of schizophrenia and related conditions. The invention provides methods for the diagnosis of schizophrenia and susceptibility to schizophrenia by detection of polymorphisms, mutations, variations, alterations in expression, etc. , in calcineurin genes or calcineurin interacting genes, or polymorphisms linked to such genes. The invention provides oligonucleotides, arrays, and antibodies for detection of polymorphisms and variants. The invention provides transgenic mice having alterations in such genes. The invention also provides methods of treating schizophrenia by administering compounds that target these genes. The invention further provides screening methods for identifying such compounds and compounds obtained by performing the screens.
-
Egr Genes As Targets For The Diagnosis And Treatment Of Schizophrenia
view source -
US Patent:20050158733, Jul 21, 2005
-
Filed:Jun 30, 2004
-
Appl. No.:10/881185
-
Inventors:David Gerber - Somerville MA, US
Joseph Gogos - Riverdale NY, US
Diana Hall - Lausanne, CH
Maria Karayiorgou - Riverdale NY, US
Susumu Tonegawa - Chestnut Hill MA, US -
International Classification:C12Q001/68
-
US Classification:435006000
-
Abstract:The present invention provides targets, methods, and reagents for the diagnosis and treatment of schizophrenia and related conditions. The invention provides methods for the diagnosis of schizophrenia and susceptibility to schizophrenia by detection of polymorphisms, mutations, variations, alterations in expression, etc., in genes encoding an EGR molecule or an EGR interacting molecule, or polymorphisms linked to such genes. The invention provides oligonucleotides, arrays, and antibodies for detection of polymorphisms and variants. The invention provides transgenic mice having alterations in such genes. The invention also provides methods of treating schizophrenia by administering compounds that target these genes. The invention further provides screening methods for identifying such compounds and compounds obtained by perfoming the screens.
-
Pak Modulators
view source -
US Patent:20100247552, Sep 30, 2010
-
Filed:Nov 9, 2007
-
Appl. No.:12/514288
-
Inventors:Susumu Tonegawa - Chestnut Hill MA, US
Mansuo L. Hayashi - Winchester MA, US
Bridget Dolan - Boston MA, US -
Assignee:MASSACHUSETTS INSTITUTE OF TECHNOLOGY - Boston MA
-
International Classification:A61K 39/395
C12Q 1/48
A61K 38/17
A61K 48/00
A61K 31/122
A61K 31/415
A61P 25/00
A61P 15/00
G01N 33/00
G01N 33/573
A01K 67/027 -
US Classification:4241721, 435 15, 514 177, 514 44 A, 514680, 514406, 800 3, 435 74, 800 18
-
Abstract:The present invention provides methods for treating fragile X syndrome and/or other neurodevelopmental disorders by administering p21-activated kinase (PAK) modulators to a patient suffering from, susceptible to, and/or exhibiting one or more symptoms of FXS and/or other neurodevelopmental disorders. The present invention provides PAK modulators and pharmaceutical compositions comprising PAK modulators. The present invention further provides methods for identifying and/or characterizing PAK modulators.
-
Targets, Methods, And Reagents For Diagnosis And Treatment Of Schizophrenia
view source -
US Patent:20110172158, Jul 14, 2011
-
Filed:Mar 16, 2011
-
Appl. No.:13/049502
-
Inventors:David J. Gerber - Somerville MA, US
Maria Karayiorgou - New York NY, US
Tsuyoshi Miyakawa - Kyoto, JP
Susumu Tonegawa - Chestnut Hill MA, US -
Assignee:MASSACHUSETTS INSTITUTE OF TECHNOLOGY - Cambridge MA
ROCKEFELLER UNIVERSITY - New York NY -
International Classification:A61K 38/02
A61P 25/18
C12Q 1/68 -
US Classification:514 175, 435 611
-
Abstract:The present invention provides targets, methods, and reagents for the diagnosis and treatment of schizophrenia and related conditions. The invention provides methods for the diagnosis of schizophrenia and susceptibility to schizophrenia by detection of polymorphisms, mutations, variations, alterations in expression, etc., in calcineurin genes or calcineurin interacting genes, or polymorphisms linked to such genes. The invention provides oligonucleotides, arrays, and antibodies for detection of polymorphisms and variants. The invention provides transgenic mice having alterations in such genes. The invention also provides methods of treating schizophrenia by administering compounds that target these genes. The invention further provides screening methods for identifying such compounds and compounds obtained by performing the screens.
-
Targets, Methods, And Reagents For Diagnosis And Treatment Of Schizophrenia
view source -
US Patent:20110288027, Nov 24, 2011
-
Filed:Aug 5, 2011
-
Appl. No.:13/204245
-
Inventors:David J. Gerber - Somerville MA, US
Maria Karayiorgou - New York NY, US
Tsuyoshi Miyakawa - Kyoto, JP
Susumu Tonegawa - Chestnut Hill MA, US -
Assignee:ROCKEFELLER UNIVERSITY - New York NY
MASSACHUSETTS INSTITUTE OF TECHNOLOGY - Cambridge MA -
International Classification:A61K 38/02
A61K 49/00
A61P 25/18
C12Q 1/68 -
US Classification:514 175, 435 612, 800 3, 435 611
-
Abstract:The present invention provides targets, methods, and reagents for the diagnosis and treatment of schizophrenia and related conditions. The invention provides methods for the diagnosis of schizophrenia and susceptibility to schizophrenia by detection of polymorphisms, mutations, variations, alterations in expression, etc., in calcineurin genes or calcineurin interacting genes, or polymorphisms linked to such genes. The invention provides oligonucleotides, arrays, and antibodies for detection of polymorphisms and variants. The invention provides transgenic mice having alterations in such genes. The invention also provides methods of treating schizophrenia by administering compounds that target these genes. The invention further provides screening methods for identifying such compounds and compounds obtained by performing the screens.
-
Small Molecule Pak Inhibitors
view source -
US Patent:20110294782, Dec 1, 2011
-
Filed:Nov 9, 2007
-
Appl. No.:12/514290
-
Inventors:Susumu Tonegawa - Chestnut Hill MA, US
Mansuo L. Hayashi - Winchester MA, US
Mazen Karaman - San Diego CA, US
Patrick P. Zarrinkar - San Diego CA, US
Daniel K. Treiber - San Diego CA, US -
Assignee:Massachusetts Institute of Technology - Boston MA
-
International Classification:A61K 31/553
A61K 31/496
A61P 25/00
A61K 31/4196
A61K 31/5377
A61K 31/404
A61K 31/454
A61K 31/4706 -
US Classification:51421108, 514326, 51425406, 514313, 514383, 5142352, 514414, 51425219
-
Abstract:The present invention provides methods for treating fragile X syndrome and/or other neurodevelopmental disorders by administering small molecule p21-activated kinase (PAK) inhibitors to a patient suffering from, susceptible to, and/or exhibiting one or more symptoms of FXS and/or other neurodevelopmental disorders. The present invention provides specific small molecule PAK inhibitors and pharmaceutical compositions comprising small molecule PAK inhibitors.
-
Heterodimeric T Lymphocyte Receptor
view source -
US Patent:49702963, Nov 13, 1990
-
Filed:Jul 27, 1989
-
Appl. No.:7/385897
-
Inventors:Haruo Saito - Arlington MA
David M. Kranz - Somerville MA
Herman N. Eisen - Waban MA
Susumu Tonegawa - Chestnut Hill MA -
Assignee:Massachusetts Institute of Technology - Cambridge MA
Board of Trustees of Leland Stanford Jr. University - Stanford CA -
International Classification:C07K 1300
C07K 1500
C12N 1500 -
US Classification:530323
-
Abstract:Disclosed is a heterodimeric T lymphocyte receptor comprising an alpha and a beta subunit. Each subunit consists of a signal peptide, variable, joining, constant, transmembrane, and cytoplasmic regions. The two subunits are connected by a disulfide bond between cysteine residues located between the constant and transmembrane region. The structure, amino acid, and nucleotide sequence of the lymphocyte receptor were determined using CDNA clones derived from a functional murine cytotoxic T lymphocyte clone. The genes corresponding to these cDNA are expressed and rearranged specifically in T cells and have significant sequence homologies to immunoglobulin V and C genes. Both the T cell receptor protein and its subunits may be produced from the cDNA clones. The protein molecules may be further used for the production of T-cell clone specific antibodies.
-
Heterodimeric T Lymphocyte Receptor
view source -
US Patent:48731900, Oct 10, 1989
-
Filed:Oct 31, 1984
-
Appl. No.:6/666988
-
Inventors:Haruo Saito - Arlington MA
David M. Kranz - Somerville MA
Herman N. Eisen - Waban MA
Susumu Tonegawa - Chestnut Hill MA -
Assignee:Massachusetts Institute of Technology - Cambridge MA
-
International Classification:C12P 2100
C12N 1500
C07K 1300
C07H 1512 -
US Classification:4351723
-
Abstract:Disclosed is a heterodimeric T lymphocyte receptor comprising an alpha and a beta subunit. Each subunit consists of a signal peptide, variable, joining, constant, transmembrane, and cytoplasmic regions. The two subunits are connected by a disulfide bond between cysteine residues located between the constant and transmembrane region. The structure, amino acid, and nucleotide sequence of the lymphocyte receptor were determined using cDNA clones derived from a functional murine cytotoxic T lymphocyte clone. The genes corresponding to these cDNA are expressed and rearranged specifically in T cells and have significant sequence homologies to immunoglobulin V and C genes. Both the T cell receptor protein and its subunits may be produced from the cDNA clones. The protein molecules may be further used for the production of T-cell clone specific antibodies.
Wikipedia References
Susumu Tonegawa
About:
Born:
06 September 1939 • Nagoya, Japan
Known for:Antibody diversity
Work:
Company:
Massachusetts Institute of Technology faculty
Education:
Academic degree:
Member of the United States National Academy of Sciences
Studied at:Curtis Institute of Music • University of California, San Diego
Area of science:Immunology • Molecular biology
Specialty:Director
Skills & Activities:
Award:
Nobel laureate in Physiology or Medicine • Recipient of the Order of Culture • Recipient of the Albert Lasker Award for Basic Medical Research • Winner • Prize
Youtube
News
'Lost' memories wiped out by Alzheimer's could be revived
view source- led to optogenetics offers the tantalising idea that tagged memories can be reactivated by light. The fascinating technique developed by the Nobel Laureate Susumu Tonegawa and his team at MIT cannot be used in humans, but it indicates that forgetfulness in AD mice may also be an access problem.
- Date: Mar 19, 2016
- Category: Health
- Source: Google
'Lost' Memories in Alzheimer Sufferers May Be Recoverable, Says Study
view source- As humans and mice tend to have a common principle in terms of memory, our findings suggest that Alzheimers disease patients, at least in their early stages, may also keep memories in their brains, which means there may be a possibility of a cure, Susumu Tonegawa, the Picower Professor of Biology
- Date: Mar 19, 2016
- Category: Health
- Source: Google
Light therapy shows promise in activating memories lost due to Alzheimer's
view source- ems to be gone, it is still there. Its a matter of how to retrieve it, senior study author Susumu Tonegawa, the Picower Professor of Biology and Neuroscience and director of the RIKEN-MIT Center for Neural Circuit Genetics at the Picower Institute for Learning and Memory, said in a news release.
- Date: Mar 19, 2016
- Category: Health
- Source: Google
'Lost' Alzheimer's Memories Can be Found
view source- ncept. That is, even if a memory seems to be gone, it is still there. Its a matter of how to retrieve it, says Susumu Tonegawa, the Picower Professor of Biology and Neuroscience and director of the RIKEN-MIT Center for Neural Circuit Genetics at the Picower Institute for Learning and Memory.
- Date: Mar 17, 2016
- Category: Health
- Source: Google
Breakthrough discovery may lead to re-booting memories for Alzheimer patients
view source- emory seems to be gone, it is still there. Its a matter of how to retrieve it, says Susumu Tonegawa, the Picower Professor of Biology and Neuroscience and director of the RIKEN-MIT Center for Neural Circuit Genetics at the Picower Institute for Learning and Memory, in the statement from MIT.
- Date: Mar 17, 2016
- Category: Health
- Source: Google
Memories 'lost' to Alzheimer's are recoverable
view source- "The important point is, this a proof of concept. That is, even if a memory seems to be gone, it is still there. It's a matter of how to retrieve it," says senior author Susumu Tonegawa from RIKEN-MIT Center for Neural Circuit Genetics.
- Date: Mar 17, 2016
- Category: Health
- Source: Google
Nerve cell stimulation 'may recall memories' in Alzheimer's patients
view source- Lead scientist Prof Susumu Tonegawa, from the Picower institute for learning and memory at the Massachusetts Institute of Technology (MIT) in the US, said: The important point is, this a proof of concept. That is, even if a memory seems to be gone, it is still there. Its a matter of how to retrievtantalising idea that tagged memories can be reactivated by light. The fascinating technique developed by the Nobel laureate Susumu Tonegawa and his team at MIT cannot be used in humans, but it indicates that forgetfulness in [mice with Alzheimers symptoms] may also be an access problem.
- Date: Mar 16, 2016
- Category: Health
- Source: Google
Let there be light: Lost memories restored to Alzheimer's mice
view source- Led by Susumu Tonegawa at the RIKEN-MIT Center for Neural Circuit Genetics, the team has successfully used a technique called optogenetics to restore memories to lab mice with Alzheimer's disease. This indicates that Alzheimer's disease affects memory retrieval, rather than formation and storage. It
- Date: Mar 16, 2016
- Category: Health
- Source: Google
Get Report for Susumu M Tonegawa from Chestnut Hill, MA, age ~85